Literature DB >> 27282417

Cognitive impairment improves the predictive validity of physical frailty for mortality in patients with advanced heart failure referred for heart transplantation.

Sunita R Jha1, Malin K Hannu2, Keren Gore3, Sungwon Chang4, Phillip Newton1, Kay Wilhelm5, Christopher S Hayward6, Andrew Jabbour6, Eugene Kotlyar7, Anne Keogh7, Kumud Dhital7, Emily Granger7, Paul Jansz7, Phillip M Spratt8, Elyn Montgomery7, Michelle Harkess7, Peta Tunicliff7, Patricia M Davidson9, Peter S Macdonald10.   

Abstract

BACKGROUND: The aim of this study was to identify whether the addition of cognitive impairment, depression, or both, to the assessment of physical frailty provides better outcome prediction in patients with advanced heart failure referred for heart transplantation (HT).
METHODS: Beginning in March 2013, all patients with advanced heart failure referred to our Transplant Unit have undergone a physical frailty assessment using the Fried frailty phenotype. Cognition was assessed with the Montreal Cognitive Assessment and depression with the Depression in Medical Illness questionnaire. We assessed the value of 4 composite frailty measures: physical frailty (PF ≥ 3 of 5 = frailty), "cognitive frailty" (CogF ≥ 3 of 6 = frail), "depressive frailty" (DepF ≥ 3 of 6 = frail), and "cognitive-depressive frailty" (ComF ≥ 3 of 7 = frail) in predicting outcomes.
RESULTS: Frailty was assessed in 156 patients (109 men, 47 women), aged 53 ± 13 years, and with a left ventricular ejection fraction of 27% ± 14%. Inclusion of cognitive impairment or depression in the definition of frailty increased the proportion classified as frail from 33% using PF to 42% using ComF. During follow-up, 28 patients died before ventricular assist device implantation or HT. Frailty was associated with significantly lower ventricular assist device- and HT-free survival, with CogF best capturing early mortality: 12-month survival for non-frail and frail cohorts was 81% ± 5% vs 58% ± 10% (p < 0.02) using PF and 85% ± 5% vs 56% ± 9% (p < 0.002) using CogF. Combining the Depression in Medical Illness score with PF or CogF did not strengthen the relationship between frailty and mortality.
CONCLUSIONS: The addition of cognitive impairment to the assessment of PF strengthened its capacity to identify advanced heart failure patients referred for HT who are at high risk of early death.
Copyright © 2016 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cognitive impairment; heart transplantation; physical frailty; survival; ventricular assist device

Mesh:

Year:  2016        PMID: 27282417     DOI: 10.1016/j.healun.2016.04.008

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  27 in total

Review 1.  The prevalence of frailty in heart failure: A systematic review and meta-analysis.

Authors:  Quin E Denfeld; Kerri Winters-Stone; James O Mudd; Jill M Gelow; Sawsan Kurdi; Christopher S Lee
Journal:  Int J Cardiol       Date:  2017-02-10       Impact factor: 4.164

Review 2.  Multidomain Frailty in Heart Failure: Current Status and Future Perspectives.

Authors:  Shinya Tanaka; Masashi Yamashita; Hiroshi Saito; Kentaro Kamiya; Daichi Maeda; Masaaki Konishi; Yuya Matsue
Journal:  Curr Heart Fail Rep       Date:  2021-04-09

3.  Combined effects of cognitive impairment and pre-frailty on future frailty and death in older Mexican Americans.

Authors:  Brian Downer; Soham Al Snih; Bret T Howrey; Mukaila A Raji; Kyriakos S Markides; Kenneth J Ottenbacher
Journal:  Aging Ment Health       Date:  2018-11-24       Impact factor: 3.658

Review 4.  Frailty in the End-Stage Lung Disease or Heart Failure Patient: Implications for the Perioperative Transplant Clinician.

Authors:  Brandi A Bottiger; Alina Nicoara; Laurie D Snyder; Paul E Wischmeyer; Jacob N Schroder; Chetan B Patel; Mani A Daneshmand; Robert N Sladen; Kamrouz Ghadimi
Journal:  J Cardiothorac Vasc Anesth       Date:  2018-08-09       Impact factor: 2.628

5.  Prevalence of Cognitive Frailty Phenotypes and Associated Factors in a Community-Dwelling Elderly Population.

Authors:  Q Ruan; F Xiao; K Gong; W Zhang; M Zhang; J Ruan; X Zhang; Q Chen; Z Yu
Journal:  J Nutr Health Aging       Date:  2020       Impact factor: 4.075

6.  Cognitive Impairment and Overall Survival in Frail Surgical Patients.

Authors:  Salima S Makhani; Frances Y Kim; Yuan Liu; Zixun Ye; Jessica L Li; Louis M Revenig; Camille P Vaughan; Theodore M Johnson; Paul S García; Kenneth Ogan; Viraj A Master
Journal:  J Am Coll Surg       Date:  2017-08-04       Impact factor: 6.113

7.  Rationale and design of the FELICITAR registry (Frailty Evaluation After List Inclusion, Characteristics and Influence on Transplantation and Results).

Authors:  Ana Ayesta; María Teresa Vidán Astiz; María Jesús Valero Masa; Javier Segovia; María Dolores García Cosío; Manuel Martínez-Sellés
Journal:  Clin Cardiol       Date:  2018-03-25       Impact factor: 2.882

8.  Frailty phenotypes and mortality after lung transplantation: A prospective cohort study.

Authors:  Jonathan P Singer; Joshua M Diamond; Michaela R Anderson; Patricia P Katz; Ken Covinsky; Michelle Oyster; Tatiana Blue; Allison Soong; Laurel Kalman; Pavan Shrestha; Selim M Arcasoy; John R Greenland; Lori Shah; Jasleen Kukreja; Nancy P Blumenthal; Imaani Easthausen; Jeffrey A Golden; Amika McBurnie; Ed Cantu; Joshua Sonett; Steven Hays; Hilary Robbins; Kashif Raza; Matthew Bacchetta; Rupal J Shah; Frank D'Ovidio; Aida Venado; Jason D Christie; David J Lederer
Journal:  Am J Transplant       Date:  2018-05-14       Impact factor: 8.086

9.  Frailty Assessment in Heart Failure: an Overview of the Multi-domain Approach.

Authors:  Julee McDonagh; Caleb Ferguson; Phillip J Newton
Journal:  Curr Heart Fail Rep       Date:  2018-02

10.  Identifying a Relationship Between Physical Frailty and Heart Failure Symptoms.

Authors:  Quin E Denfeld; Kerri Winters-Stone; James O Mudd; Shirin O Hiatt; Christopher S Lee
Journal:  J Cardiovasc Nurs       Date:  2018 Jan/Feb       Impact factor: 2.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.